All In Biotech

Drug Trial Radar · NCT06383871

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

An Open, Multicenter Phase I Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-7058 Monotherapy in Patients With Advanced Solid Tumour With KRAS G12C Mutation

Last checked: Nov 20, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

233

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Jun 2026

Study completion Jun 2026

Sponsor

Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.

Conditions

  • Advanced Malignant Tumour

Interventions

  • HRS-7058 capsule/ HRS-7058 tabletDrug

    HRS-7058 capsule/ HRS-7058 tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
  2. maximum tolerated dose (MTD)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
  3. Phase II recommended dose (RP2D)Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
  4. Safety endpoints: adverse events (AE)Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 21 months]

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.